A clinical study to assess the efficacy and safety of three doses of vildagliptin in patients with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 01 May 2012 Actual patient number added 639 according to ClinicalTrials.gov.
- 01 May 2012 Actual end date (October 2005) added as reported by ClinicalTrials.gov.